Evidence map›Paper›PMID 29427314›Full record

ArticleJournal of diabetes investigation2018

Analysis of the effect of seasonal administration on the efficacy of sitagliptin: Subanalysis of the Januvia Multicenter Prospective Trial in Type 2 Diabetes Study.

Hiroshi Sakura, Naotake Hashimoto, Kazuo Sasamoto, Hiroshi Ohashi, Sumiko Hasumi, Noriko Ujihara, Tadasu Kasahara, Osamu Tomonaga, Hideo Nunome, Masashi Honda and 2 more

Abstract readMulticenter Study
In one paragraph

Article in Journal of diabetes investigation, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Hiroshi SakuraDepartment of Medicine, Tokyo Women's Medical University, Medical Center East, Tokyo, Japan.
Naotake HashimotoDepartment of Diabetes, Endocrine and Metabolic Diseases, Tokyo Women's Medical University Yachiyo Medical Center, Chiba, Japan.
Kazuo SasamotoInternal Medicine, Suzuki Clinic, Tokyo, Japan.
Hiroshi OhashiInternal Medicine, Oyama East Clinic, Tochigi, Japan.
Sumiko HasumiInternal Medicine, Nishiyamado-Keiwa Hospital, Ibaraki, Japan.
Noriko UjiharaDepartment of Medicine, Diabetes Center, Institute of Geriatrics, Tokyo Women's Medical University, Tokyo, Japan.
Tadasu KasaharaJosai Hospital, Tokyo, Japan.
Osamu TomonagaDiabetes and lifestyle Center, Tomonaga Clinic, Tokyo, Japan.
Hideo NunomeDiabetes Center, Edogawa Hospital, Medical Plaza Shinozaki, Tokyo, Japan.
Masashi HondaNishikawa Clinic, Tokyo, Japan.
Yasuhiko IwamotoTokyo Women's Medical University/The Institute for Adult Diseases, Asahi Life Foundation, Tokyo, Japan.
JAMP Study Investigators

Funding

Japan Diabetes Foundation
6 · The paper itself

Abstract

AIMS/

introductionHemoglobin A1c (HbA1c) levels in patients with type 2 diabetes mellitus fluctuate throughout the year. However, there are few studies that have evaluated the therapeutic effect of hypoglycemic agents while considering such fluctuations. In a multicenter study (Januvia Multicenter Prospective Trial in Type 2 Diabetes Study), pretreatment patients with type 2 diabetes mellitus were divided into seven groups and given sitagliptin for 1 year. The aim of the present study was to evaluate the differences in the therapeutic effect, and the efficacy of sitagliptin in patients with type 2 diabetes mellitus based on the month the administration of the drug began as a subanalysis of the Januvia Multicenter Prospective Trial in Type 2 Diabetes Study. MATERIALS AND

methodsPatients with type 2 diabetes mellitus were divided into four groups according to the month of initiation of sitagliptin. Changes in HbA1c in each group were compared at 3 and 12 months after administration of sitagliptin. As a negative correlation has been reported between baseline HbA1c and the degree of change after administration of sitagliptin, an analysis using the residual error from the approximate line was carried out.

resultsIn the analysis of the degree of change in HbA1c, patients in the group in which administration of sitagliptin was started between August and October had the lowest degree of improvement at 3 months after starting sitagliptin. However, there was no significant intergroup difference in improvement at 12 months after the start of sitagliptin. The same result was also obtained in residual analysis.

conclusionsThe present study suggested that the season of administration of sitagliptin influenced the subsequent hypoglycemic effect even after analysis excluding the influence of HbA1c value at the start of treatment. This study provides possibility, showing that seasonal fluctuations have an effect on the efficacy of antidiabetic drugs.

Indexed as

SeasonsAgedDiabetes Mellitus, Type 2Dipeptidyl-Peptidase IV InhibitorsDrug Administration ScheduleFemaleGlycated HemoglobinHumansHypoglycemic AgentsMaleMiddle AgedProspective StudiesSitagliptin PhosphateTreatment OutcomeDipeptidyl-Peptidase IV InhibitorsGlycated Hemoglobinhemoglobin A1c protein, humanHypoglycemic AgentsSitagliptin PhosphateSeasonal fluctuation in hemoglobin A1cSitagliptinType 2 diabetes mellitus

Identifiers

PMID29427314
PMCPMC6123028

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.